161 related articles for article (PubMed ID: 2179793)
21. Pharmacokinetics of a modified-release estrogen tablet.
Bhamra R; Kaercher U; Oleary CM
J Reprod Med; 2010; 55(9-10):404-10. PubMed ID: 21043366
[TBL] [Abstract][Full Text] [Related]
22. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
Shufelt CL; Manson JE
J Clin Endocrinol Metab; 2021 Apr; 106(5):1245-1254. PubMed ID: 33506261
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous hormone replacement therapy.
Tzingounis VA; Perdikaris AG; Lioutas G; Dimopoulos D
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):64-6. PubMed ID: 8365523
[TBL] [Abstract][Full Text] [Related]
24. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
[TBL] [Abstract][Full Text] [Related]
25. Relative value of transdermal and oral estrogen therapy in various clinical situations.
Lufkin EG; Ory SJ
Mayo Clin Proc; 1994 Feb; 69(2):131-5. PubMed ID: 8309263
[TBL] [Abstract][Full Text] [Related]
26. Absorption and metabolic effects of different types of estrogens and progestogens.
Lobo RA
Obstet Gynecol Clin North Am; 1987 Mar; 14(1):143-67. PubMed ID: 3306517
[TBL] [Abstract][Full Text] [Related]
27. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
Simon JA; Archer DF; Constantine GD; Pickar JH; Amadio JM; Bernick B; Graham S; Mirkin S
Maturitas; 2017 May; 99():51-58. PubMed ID: 28364869
[TBL] [Abstract][Full Text] [Related]
28. Nonoral routes of estrogen administration.
Cedars MI; Judd HL
Obstet Gynecol Clin North Am; 1987 Mar; 14(1):269-98. PubMed ID: 3306522
[TBL] [Abstract][Full Text] [Related]
29. Are all estrogens the same?
Coelingh Bennink HJ
Maturitas; 2004 Apr; 47(4):269-75. PubMed ID: 15063479
[TBL] [Abstract][Full Text] [Related]
30. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
[TBL] [Abstract][Full Text] [Related]
31. [Low dose estrogens and synthetic estrogens. Options for hormone replacement therapy in climacteric women].
Velasco-Murillo V
Rev Med Inst Mex Seguro Soc; 2007; 45(4):381-7. PubMed ID: 17949576
[TBL] [Abstract][Full Text] [Related]
32. Biologic effects of transdermal estradiol.
Chetkowski RJ; Meldrum DR; Steingold KA; Randle D; Lu JK; Eggena P; Hershman JM; Alkjaersig NK; Fletcher AP; Judd HL
N Engl J Med; 1986 Jun; 314(25):1615-20. PubMed ID: 3012339
[TBL] [Abstract][Full Text] [Related]
33. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause.
Watts NB; Notelovitz M; Timmons MC; Addison WA; Wiita B; Downey LJ
Obstet Gynecol; 1995 Apr; 85(4):529-37. PubMed ID: 7898828
[TBL] [Abstract][Full Text] [Related]
34. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
35. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
36. To clot, or not to clot: The dilemma of hormone treatment options for menopause.
Booyens RM; Engelbrecht AM; Strauss L; Pretorius E
Thromb Res; 2022 Oct; 218():99-111. PubMed ID: 36030662
[TBL] [Abstract][Full Text] [Related]
37. Safety and benefit considerations for menopausal hormone therapy.
Pickar JH; Archer DF; Kagan R; Pinkerton JV; Taylor HS
Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration.
Schindler AE; Bolt HM; Zwirner M; Hochlehnert G; Göser R
Arzneimittelforschung; 1982; 32(7):787-91. PubMed ID: 6289846
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women.
Vongpatanasin W; Tuncel M; Wang Z; Arbique D; Mehrad B; Jialal I
J Am Coll Cardiol; 2003 Apr; 41(8):1358-63. PubMed ID: 12706932
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
